Catheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook

Core Insights - Catheter Precision, Inc. has reported a surge in hospital evaluations and approvals for its LockeT suture retention device, indicating strong progress in product adoption both domestically and internationally as of Q1 2026 [1][2] Product Adoption - The company achieved its highest recorded revenue for January and has entered several international markets, securing evaluations at additional high-volume centers in the U.S. These evaluations are essential for long-term purchasing agreements [2] - Initial feedback from hospital partners suggests that LockeT effectively addresses the need for efficient and cost-effective wound closure, with expectations for evaluations to transition into permanent adoption [3] Product Details - LockeT is a Class 1 suture retention device registered with the FDA and has received CE Mark approval, designed to assist in wound closure after percutaneous venous punctures [4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [5] Operational Efficiency - LockeT's design allows for rapid staff onboarding, with training completed in several days at major institutions, enhancing operational efficiency [9] - The device facilitates same-day discharge and reduces post-procedural bed rest, presenting a strong economic case for hospitals [9] International Expansion - The company is expanding into the European closure market, leveraging its CE Mark approval and the economic advantages of LockeT [9]